Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Herpesvirus latency confers symbiotic protection from bacterial infection

Abstract

All humans become infected with multiple herpesviruses during childhood. After clearance of acute infection, herpesviruses enter a dormant state known as latency. Latency persists for the life of the host and is presumed to be parasitic, as it leaves the individual at risk for subsequent viral reactivation and disease1. Here we show that herpesvirus latency also confers a surprising benefit to the host. Mice latently infected with either murine gammaherpesvirus 68 or murine cytomegalovirus, which are genetically highly similar to the human pathogens Epstein–Barr virus and human cytomegalovirus2, respectively, are resistant to infection with the bacterial pathogens Listeria monocytogenes and Yersinia pestis. Latency-induced protection is not antigen specific but involves prolonged production of the antiviral cytokine interferon-γ and systemic activation of macrophages. Latency thereby upregulates the basal activation state of innate immunity against subsequent infections. We speculate that herpesvirus latency may also sculpt the immune response to self and environmental antigens through establishment of a polarized cytokine environment. Thus, whereas the immune evasion capabilities and lifelong persistence of herpesviruses are commonly viewed as solely pathogenic, our data suggest that latency is a symbiotic relationship with immune benefits for the host.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Macrophages are activated during γHV68 latency.
Figure 2: Latent herpesvirus infection renders mice resistant to L. monocytogenes.
Figure 3: Latently infected mice are resistant to Y. pestis but not WNV.
Figure 4: Mechanism of enhanced innate immunity in latently infected mice.

Similar content being viewed by others

References

  1. Rickinson, A. B. & Kieff, E. Fields Virology (eds Knipe, D. M. & Howley, P.) 2655– 2670 (Lippincott-Raven, Philadelphia, 2007)

    Google Scholar 

  2. Virgin, H. W. et al. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J. Virol. 71, 5894– 5904 (1997)

    CAS  PubMed  PubMed Central  Google Scholar 

  3. McClellan, K. B., Gangappa, S., Speck, S. H. & Virgin, H. W. Antibody-independent control of gamma-herpesvirus latency via B cell induction of anti-viral T cell responses. PLoS Pathog. 2, e58 (2006)

    Article  Google Scholar 

  4. Weck, K. E., Kim, S. S., Virgin, H. W. & Speck, S. H. Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells. J. Virol. 73, 3273– 3283 (1999)

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Edelson, B. T. & Unanue, E. R. Immunity to Listeria infection. Curr. Opin. Immunol. 12, 425– 431 (2000)

    Article  CAS  Google Scholar 

  6. Moorman, N. J., Willer, D. O. & Speck, S. H. The gammaherpesvirus 68 latency-associated nuclear antigen homolog is critical for the establishment of splenic latency. J. Virol. 77, 10295– 10303 (2003)

    Article  CAS  Google Scholar 

  7. Cathelyn, J. S., Crosby, S. D., Lathem, W. W., Goldman, W. E. & Miller, V. L. RovA, a global regulator of Yersinia pestis, specifically required for bubonic plague. Proc. Natl Acad. Sci. USA 103, 13514– 13519 (2006)

    Article  ADS  CAS  Google Scholar 

  8. Braaten, D. C. et al. Effective control of chronic gamma-herpesvirus infection by unconventional MHC Class Ia-independent CD8 T cells. PLoS Pathog. 2, e37 (2006)

    Article  Google Scholar 

  9. Sarawar, S. R. et al. Gamma interferon is not essential for recovery from acute infection with murine gammaherpesvirus 68. J. Virol. 71, 3916– 3921 (1997)

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Tibbetts, S. A., Van Dyk, L., Speck, S. H. & Virgin, H. W. Immune control of the number and reactivation phenotype of cells latently infected with a gamma-herpesvirus. J. Virol. 76, 7125– 7132 (2002)

    Article  CAS  Google Scholar 

  11. Christensen, J. P. & Doherty, P. C. Quantitative analysis of the acute and long-term CD4+ T-cell response to a persistent gammaherpesvirus. J. Virol. 73, 4279– 4283 (1999)

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Flano, E., Woodland, D. L., Blackman, M. A. & Doherty, P. C. Analysis of virus-specific CD4+ T cells during long-term gammaherpesvirus infection. J. Virol. 75, 7744– 7748 (2001)

    Article  CAS  Google Scholar 

  13. Polic, B. et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 188, 1047– 1054 (1998)

    Article  CAS  Google Scholar 

  14. Mackaness, G. B. The immunological basis of acquired cellular resistance. J. Exp. Med. 120, 105– 120 (1964)

    Article  CAS  Google Scholar 

  15. Mackaness, G. B. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J. Exp. Med. 129, 973– 992 (1969)

    Article  CAS  Google Scholar 

  16. Selin, L. K. et al. Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol. Rev. 211, 164– 181 (2006)

    Article  CAS  Google Scholar 

  17. Berg, R. E., Crossley, E., Murray, S. & Forman, J. Memory CD8+ T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen. J. Exp. Med. 198, 1583– 1593 (2003)

    Article  CAS  Google Scholar 

  18. Tan, L. C. et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol. 162, 1827– 1835 (1999)

    CAS  PubMed  Google Scholar 

  19. Dunn, H. S. et al. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J. Infect. Dis. 186, 15– 22 (2002)

    Article  CAS  Google Scholar 

  20. Amyes, E. et al. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J. Exp. Med. 198, 903– 911 (2003)

    Article  CAS  Google Scholar 

  21. Hislop, A. D. et al. Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. J. Clin. Invest. 115, 2546– 2555 (2005)

    Article  CAS  Google Scholar 

  22. Theil, D. et al. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am. J. Pathol. 163, 2179– 2184 (2003)

    Article  CAS  Google Scholar 

  23. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539– 545 (2001)

    Article  CAS  Google Scholar 

  24. Schaub, B., Lauener, R. & von Mutius, E. The many faces of the hygiene hypothesis. J. Allergy Clin. Immunol. 117, 969– 977 (2006)

    Article  Google Scholar 

  25. Takeuchi, K. et al. Prevalence of Epstein-Barr virus in Japan: trends and future prediction. Pathol. Int. 56, 112– 116 (2006)

    Article  Google Scholar 

  26. Nilsson, C. et al. Does early EBV infection protect against IgE sensitization? J. Allergy Clin. Immunol. 116, 438– 444 (2005)

    Article  CAS  Google Scholar 

  27. Roizman, B. & Pellett, P. E. Fields Virology (eds Knipe, D. M. & Howley, P. M.) 2475– 2499 (Lippincott-Raven, Philadelphia, 2007)

    Google Scholar 

  28. Shrestha, B. et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J. Virol. 80, 5338– 5348 (2006)

    Article  CAS  Google Scholar 

  29. McClellan, J. S., Tibbetts, S. A., Gangappa, S., Brett, K. A. & Virgin, H. W. Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gamma-herpesvirus latency. J. Virol. 78, 6836– 6845 (2004)

    Article  CAS  Google Scholar 

  30. Edelson, B. T. & Unanue, E. R. Intracellular antibody neutralizes Listeria growth. Immunity 14, 503– 512 (2001)

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported by grants from the National Institutes of Health (E.S.B., V.L.M. & H.W.V.), an Abbott Scholar Award (D.W.W.) and a Cancer Research Institute postdoctoral fellowship (E.S.B.).

Author Contributions The original hypothesis of the article was formulated by E.S.B. and H.W.V. E.S.B. and D.W.W performed all experiments except those characterizing Y. pestis infection (J.S.C. and V.L.M.) and WNV infection (M.E. and M.S.D.). K.A.B.-M. made the initial observation of chronic IFNγ secretion during latency. The manuscript was written by E.S.B., D.W.W., and H.W.V. and all authors commented on data and conclusions prior to submission.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Herbert W. Virgin IV.

Ethics declarations

Competing interests

Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests.

Supplementary information

Supplementary Figure

This file contains Supplementary Figure S1 illustrating how latent infection with γHV68 or MCMV results in chronic, systemic macrophage activation. (PDF 257 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barton, E., White, D., Cathelyn, J. et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447, 326–329 (2007). https://doi.org/10.1038/nature05762

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature05762

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing